OpenLB
Open Library of Bioscience
Advanced Search
Research square
Oct 07, 2020;

Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters.

Shuofeng Yuan, Xin Yin, XiangZhi Meng, Jasper Chan, Zi-Wei Ye, Laura Riva, Lars Pache, Chris Chun-Yiu Chan, Pok-Man Lai, Chris Chan, Vincent Poon, Naoko Matsunaga, Yuan Pu, Chun-Kit Yuen, Jianli Cao, Ronghui Liang, Kaiming Tang, Li Sheng, Yushen Du, Wan Xu, Kong-Hung Sze, Jinxia Zhang, Hin Chu, Kin-Hang Kok, Kelvin To, Dong-Yan Jin, Ren Sun, Sumit Chanda, Kwok-Yung Yuen
Author Information
  1. Shuofeng Yuan: University of Hong Kong.
  2. Xin Yin: Sanford Burnham Prebys Medical Discovery Institute. ORCID
  3. XiangZhi Meng: University of Hong Kong.
  4. Jasper Chan: The University of Hong Kong.
  5. Zi-Wei Ye: State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong.
  6. Laura Riva: Sanford Burnham Prebys Medical Discovery Institute.
  7. Lars Pache: Sanford Burnham Prebys Medical Discovery Institute. ORCID
  8. Chris Chun-Yiu Chan: University of Hong Kong.
  9. Pok-Man Lai: University of Hong Kong.
  10. Chris Chan: The University of Hong Kong.
  11. Vincent Poon: The University of Hong Kong.
  12. Naoko Matsunaga: Sanford Burnham Prebys Medical Discovery Institute.
  13. Yuan Pu: Sanford Burnham Prebys Medical Discovery Institute.
  14. Chun-Kit Yuen: University of Hong Kong.
  15. Jianli Cao: The University of Hong Kong.
  16. Ronghui Liang: University of Hong Kong.
  17. Kaiming Tang: University of Hong Kong.
  18. Li Sheng: UCLA.
  19. Yushen Du: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA. ORCID
  20. Wan Xu: University of Hong Kong.
  21. Kong-Hung Sze: University of Hong Kong.
  22. Jinxia Zhang: Department of microbiology.
  23. Hin Chu: University of Hong Kong.
  24. Kin-Hang Kok: The University of Hong Kong. ORCID
  25. Kelvin To: The University of Hong Kong. ORCID
  26. Dong-Yan Jin: University of Hong Kong. ORCID
  27. Ren Sun: The University of Hong Kong.
  28. Sumit Chanda: Sanford Burnham Prebys Medical Discovery Institute. ORCID
  29. Kwok-Yung Yuen: University of Hong Kong. ORCID
PMID: 33052331 DOI: 10.21203/rs.3.rs-86169/v1

Abstract

COVID-19 pandemic is the third zoonotic coronavirus (CoV) outbreak of the century after severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) since 2012. Treatment options for CoVs are largely lacking. Here, we show that clofazimine, an anti-leprosy drug with a favorable safety and pharmacokinetics profile, possesses pan-coronaviral inhibitory activity, and can antagonize SARS-CoV-2 replication in multiple systems, including the human embryonic stem cell-derived cardiomyocytes and lung cultures. The FDA-approved molecule was found to inhibit multiple steps of viral replication, suggesting multiple underlying antiviral mechanisms. In a hamster model of SARS-CoV-2 pathogenesis, prophylactic or therapeutic administration of clofazimine significantly reduced viral load in the lung and fecal viral shedding, and also prevented cytokine storm associated with viral infection. Additionally, clofazimine exhibited synergy when administered with remdesivir. Since clofazimine is orally bioavailable and has a comparatively low manufacturing cost, it is an attractive clinical candidate for outpatient treatment and remdesivir-based combinatorial therapy for hospitalized COVID-19 patients, particularly in developing countries. Taken together, our data provide evidence that clofazimine may have a role in the control of the current pandemic SARS-CoV-2, endemic MERS-CoV in the Middle East, and, possibly most importantly, emerging CoVs of the future.

References

  1. BMJ Open. 2014 Jan 02;4(1):e004143 [PMID: 24384902]
  2. JAMA Intern Med. 2020 Nov 01;180(11):1447-1452 [PMID: 32780793]
  3. Sci Transl Med. 2017 Jun 28;9(396): [PMID: 28659436]
  4. OMICS. 2012 May;16(5):284-7 [PMID: 22455463]
  5. Nat Commun. 2019 Jan 10;10(1):120 [PMID: 30631056]
  6. Nat Rev Microbiol. 2016 Aug;14(8):523-34 [PMID: 27344959]
  7. J Antimicrob Chemother. 2012 Feb;67(2):290-8 [PMID: 22020137]
  8. Genome Biol. 2013 Apr 25;14(4):R36 [PMID: 23618408]
  9. Cell Biosci. 2020 Mar 16;10:40 [PMID: 32190290]
  10. Cell. 2020 Apr 16;181(2):271-280.e8 [PMID: 32142651]
  11. Nature. 2020 Oct;586(7827):113-119 [PMID: 32707573]
  12. Eur Respir J. 2017 Mar 22;49(3): [PMID: 28331043]
  13. Clin Microbiol Rev. 2015 Apr;28(2):465-522 [PMID: 25810418]
  14. PLoS One. 2008;3(12):e4009 [PMID: 19104661]
  15. Lancet. 2020 May 30;395(10238):1695-1704 [PMID: 32401715]
  16. Bioinformatics. 2014 Apr 1;30(7):923-30 [PMID: 24227677]
  17. Clin Microbiol Rev. 2007 Oct;20(4):660-94 [PMID: 17934078]
  18. Eur Respir J. 2017 Mar 22;49(3): [PMID: 28331044]
  19. N Engl J Med. 2020 Sep 3;383(10):994 [PMID: 32649078]
  20. Science. 2020 Oct 23;370(6515): [PMID: 32972995]
  21. Clin Infect Dis. 2020 Dec 3;71(9):2428-2446 [PMID: 32215622]
  22. Lancet. 2020 May 16;395(10236):1569-1578 [PMID: 32423584]
  23. N Engl J Med. 2020 Nov 5;383(19):1827-1837 [PMID: 32459919]
  24. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4 [PMID: 945233]
  25. Clin Infect Dis. 2021 Jul 15;73(2):e503-e512 [PMID: 32667973]
  26. Tuberculosis (Edinb). 2004;84(6):365-73 [PMID: 15525560]
  27. Drug Metab Dispos. 2018 Jan;46(1):26-32 [PMID: 29038231]
  28. Antimicrob Agents Chemother. 2016 May 23;60(6):3470-9 [PMID: 27021320]
  29. Science. 2020 Oct 23;370(6515): [PMID: 32972996]
  30. Science. 2020 May 22;368(6493):860-868 [PMID: 32291278]
  31. Genome Res. 2003 Nov;13(11):2498-504 [PMID: 14597658]
  32. Cell Host Microbe. 2020 May 13;27(5):841-848.e3 [PMID: 32289263]
  33. Drug Metab Dispos. 1981 Nov-Dec;9(6):521-4 [PMID: 6120809]
  34. Mol Pharm. 2011 Oct 3;8(5):1742-9 [PMID: 21800872]
  35. Int J Tuberc Lung Dis. 2013 Aug;17(8):1001-7 [PMID: 23541151]
  36. J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4 [PMID: 32425269]
  37. Cell Rep Med. 2020 Jul 21;1(4):100052 [PMID: 32835305]
  38. Lancet Infect Dis. 2020 May;20(5):565-574 [PMID: 32213337]
  39. Nature. 2020 Aug;584(7821):463-469 [PMID: 32717743]
  40. Med Mal Infect. 2020 Jun;50(4):382-383 [PMID: 32259560]
  41. Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493 [PMID: 32246720]
  42. Clin Infect Dis. 2020 Sep 12;71(6):1400-1409 [PMID: 32270184]
  43. Science. 2020 Aug 7;369(6504):718-724 [PMID: 32661059]
  44. Clin Infect Dis. 2015 May 1;60(9):1361-7 [PMID: 25605283]
  45. Stem Cells Dev. 2014 Jul 15;23(14):1704-16 [PMID: 24564569]

Grants

  1. HHSN272201400008C/NIAID NIH HHS
  2. U19 AI118610/NIAID NIH HHS
  3. U19 AI135972/NIAID NIH HHS
  4. U19 AI142733/NIAID NIH HHS
Preprint

Links to CNCB-NGDC Resources

GEN: GEND000421 (Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters)
GEN: GEND000422 (Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters)

Word Cloud

Similar Articles

Cited By